Novartis AG NVS
At closeNov 4, 2026, 4:00 PM EST
After hours · Nov 4, 4:00 PM ET
- YTD
- +19.66%
- 1 year
- +31.97%
- Market cap
- 311.59B
- Revenue (ttm)
- 57.36B
- Profit margin
- 17.49%
- EPS (ttm)
- 5.24
- Shares out
- 1.89B
- P/E ratio
- 31.48
- Forward P/E
- 16.60
- Dividend
- 4.74 (2.98%)
- Ex-dividend date
- Mar 10, 2026
- YTD return
- +19.66%
- 1-year return
- +31.97%
- Volume
- 1.74M
- Avg volume
- 2.04M
- Open
- 163.69
- Previous close
- 159.26
- Day's range
- 162.16 – 165.05
- 52-week range
- 123.24 – 170.46
- Beta
- 0.46
- Analysts
- Hold
- Price target
- 154.80 (-6.2%)
- Earnings date
- Feb 3, 2027
5D +2.37 (+1.46%)
Key statistics
- Enterprise value
- 340.56B
- PEG ratio
- 3.80
- Price / sales
- 5.43
- Price / book
- 8.37
- Dividend yield
- 2.98%
- Payout ratio
- 90.46%
- Revenue growth
- 4.70%
- Free cash flow
- 11.27B
- Total cash
- 8.87B
- Total debt
- 48.31B
- Return on equity
- 24.33%
- Short % of float
- 0.30%
- 50-day average
- 148.48
- 200-day average
- 151.97
Analyst view
Consensus: hold
- Target (low)
- 130.00
- Target (mean)
- 154.80
- Target (high)
- 185.00
- Strong buy3
- Buy2
- Hold4
- Sell1
- Strong sell1
Next earnings
Feb 3, 2027
Expected Feb 3, 2027. Consensus EPS estimate 2.23.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 3, 2027 | Dec 30, 2026 | 2.23 | — | — | — |
| Oct 27, 2026 | Sep 30, 2026 | 2.25 | 2.46 | +0.21 | +9.33% |
| Jul 21, 2026 | Jun 30, 2026 | 2.17 | 2.41 | +0.24 | +11.06% |
| Apr 28, 2026 | Mar 31, 2026 | 2.11 | 1.99 | -0.12 | -5.69% |
| Feb 4, 2026 | Dec 31, 2025 | 1.99 | 2.03 | +0.04 | +2.01% |
| Oct 28, 2025 | Sep 29, 2025 | 2.26 | 2.25 | -0.01 | -0.44% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 30, 2026 | Deutsche Bank | down | Hold | Sell |
| Sep 10, 2026 | HSBC | up | Reduce | Hold |
| Mar 26, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Jan 6, 2026 | Barclays | up | Underweight | Equal-Weight |
| Dec 8, 2025 | JP Morgan | up | Neutral | Overweight |
| Sep 12, 2025 | Goldman Sachs | down | Neutral | Sell |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease. It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in chronic and/or accelerated phase; Xolair for treating allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Stills disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma to treat genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran) to reduce LDL cholesterol. Novartis AG has a strategic alliance with CAS for enhancing reaction data accessibility and supporting AI-enabled research. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- Switzerland
- Website
- novartis.com
News
Novartis: 3 Key Takeaways for Long-Term Investors 
3 Stocks to Watch Following Guidance Upgrades 
BioArctic AB Announces Novartis Terminates Their 2025 Option, Collaboration And License Deal; BioArctic To Retain Full $30M Upfront Payment 
BioArctic collaborator Novartis terminates agreement 
6 dividend stocks for investors who want to cut their exposure to the S&P 500 
Allarity Therapeutics Settles $4.9M Novartis Liability For $1M Payment 
Novartis heart drug failure leaves doctors seeking evidence for genetic cholesterol target 
Companies promised AI gains— here's how the payoff showed up in earnings 
Novartis: Q3 2026 Earnings Confirm 'Hold' Recommendation Based On Balanced Approach 
All You Need to Know About Novartis (NVS) Rating Upgrade to Buy
Your note
Sign in to keep a note on NVS — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fisher Asset Management, LLC | 0.76% | 15,523,378 | 2.56B | Jun 29, 2026 |
| Morgan Stanley | 0.43% | 8,726,827 | 1.44B | Jun 29, 2026 |
| Dimensional Fund Advisors LP | 0.40% | 8,117,586 | 1.34B | Jun 29, 2026 |
| Primecap Management Company | 0.32% | 6,592,124 | 1.09B | Jun 29, 2026 |
| LOOMIS SAYLES & CO L P | 0.26% | 5,239,309 | 864.59M | Jun 29, 2026 |
| Bank of America Corporation | 0.24% | 4,909,938 | 810.24M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD CHESTER FUNDS-Vanguard PRIMECAP Fund | 0.21% | 4,252,875 | 701.81M | Jun 29, 2026 |
| DFA INVESTMENT DIMENSIONS GROUP INC-Intl Core Eqy. 2 PORT. | 0.10% | 2,060,639 | 340.05M | Jul 30, 2026 |
| LOOMIS SAYLES FUNDS II-Loomis Sayles Growth Fund | 0.07% | 1,417,894 | 233.98M | Jun 29, 2026 |
| VANGUARD HORIZON FUNDS-Vanguard Capital Opportunity Fund | 0.06% | 1,211,220 | 199.88M | Jun 29, 2026 |
| Franklin Mutual Series Funds-FRANKLIN MUTUAL GLOBAL DISCOVERY FUND | 0.06% | 1,192,174 | 196.73M | Jun 29, 2026 |
| JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund | 0.05% | 949,726 | 156.72M | Jun 29, 2026 |